Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autoren: Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
Formato: Artigo
Idioma:inglês
Publicado em: Philipps-Universität Marburg 2023
Assuntos:
Immunology
Medizin
Biotechnology
Microbiology
Medical sciences Medicine
Acesso em linha:Texto integral em PDF
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Texto integral em PDF

Detalhes do Exemplar
Área/Cota: urn:nbn:de:hebis:04-es2024-04361
Publikationsdatum: 2024-01-17
Fonte: Erstveröffentlichung: Horvath, D., Temperton, N., Mayora-Neto, M. et al. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice. Sci Rep 13, 4648 (2023). https://doi.org/10.1038/s41598-023-31198-3
Downloads: 9 (2024)
Lizenz: https://creativecommons.org/licenses/by/4.0
Zugangs-URL: https://archiv.ub.uni-marburg.de/es/2024/0436
https://doi.org/10.1038/s41598-023-31198-3

Registos relacionados